SG11201606979TA - Anti-egfrviii antibodies and uses thereof - Google Patents

Anti-egfrviii antibodies and uses thereof

Info

Publication number
SG11201606979TA
SG11201606979TA SG11201606979TA SG11201606979TA SG11201606979TA SG 11201606979T A SG11201606979T A SG 11201606979TA SG 11201606979T A SG11201606979T A SG 11201606979TA SG 11201606979T A SG11201606979T A SG 11201606979TA SG 11201606979T A SG11201606979T A SG 11201606979TA
Authority
SG
Singapore
Prior art keywords
egfrviii antibodies
egfrviii
antibodies
Prior art date
Application number
SG11201606979TA
Other languages
English (en)
Inventor
Jessica R Kirshner
Douglas Macdonald
Gavin Thurston
Joel H Martin
Frank Delfino
Thomas Nittoli
Marcus Kelly
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52875228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201606979T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201606979TA publication Critical patent/SG11201606979TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201606979TA 2014-03-11 2015-03-10 Anti-egfrviii antibodies and uses thereof SG11201606979TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461950963P 2014-03-11 2014-03-11
PCT/US2015/019722 WO2015138460A1 (en) 2014-03-11 2015-03-10 Anti-egfrviii antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11201606979TA true SG11201606979TA (en) 2016-09-29

Family

ID=52875228

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201606979TA SG11201606979TA (en) 2014-03-11 2015-03-10 Anti-egfrviii antibodies and uses thereof

Country Status (31)

Country Link
US (4) US9475875B2 (enrdf_load_stackoverflow)
EP (1) EP3126388B1 (enrdf_load_stackoverflow)
JP (1) JP6632984B2 (enrdf_load_stackoverflow)
KR (1) KR102399005B1 (enrdf_load_stackoverflow)
CN (1) CN106459199B (enrdf_load_stackoverflow)
AU (1) AU2015229591B2 (enrdf_load_stackoverflow)
BR (1) BR112016020752B1 (enrdf_load_stackoverflow)
CA (1) CA2940685C (enrdf_load_stackoverflow)
CL (1) CL2016002252A1 (enrdf_load_stackoverflow)
CY (1) CY1121870T1 (enrdf_load_stackoverflow)
DK (1) DK3126388T3 (enrdf_load_stackoverflow)
EA (1) EA035809B1 (enrdf_load_stackoverflow)
ES (1) ES2736126T3 (enrdf_load_stackoverflow)
HR (1) HRP20191335T1 (enrdf_load_stackoverflow)
HU (1) HUE045307T2 (enrdf_load_stackoverflow)
IL (1) IL247407B (enrdf_load_stackoverflow)
LT (1) LT3126388T (enrdf_load_stackoverflow)
MA (1) MA39313B1 (enrdf_load_stackoverflow)
ME (1) ME03525B (enrdf_load_stackoverflow)
MX (1) MX373280B (enrdf_load_stackoverflow)
MY (1) MY178160A (enrdf_load_stackoverflow)
NZ (1) NZ724229A (enrdf_load_stackoverflow)
PH (1) PH12016501680A1 (enrdf_load_stackoverflow)
PL (1) PL3126388T3 (enrdf_load_stackoverflow)
PT (1) PT3126388T (enrdf_load_stackoverflow)
RS (1) RS59077B1 (enrdf_load_stackoverflow)
SG (1) SG11201606979TA (enrdf_load_stackoverflow)
SI (1) SI3126388T1 (enrdf_load_stackoverflow)
SM (1) SMT201900439T1 (enrdf_load_stackoverflow)
WO (1) WO2015138460A1 (enrdf_load_stackoverflow)
ZA (1) ZA201605894B (enrdf_load_stackoverflow)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
EA035809B1 (ru) 2014-03-11 2020-08-14 Регенерон Фармасьютикалс, Инк. АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
US20160176962A1 (en) * 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
MD3365373T2 (ro) * 2015-10-23 2021-08-31 Merus Nv Molecule de legare care inhibă dezvoltarea cancerului
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
JP7313684B2 (ja) * 2016-11-21 2023-07-25 キュレアブ ゲーエムベーハー 抗ｇｐ７３抗体及びイムノコンジュゲート
KR102660715B1 (ko) * 2017-02-10 2024-04-26 리제너론 파마슈티칼스 인코포레이티드 면역-pet 이미지화를 위한 방사선 라벨링된 항-lag3 항체
SG11201912548XA (en) 2017-07-06 2020-01-30 Regeneron Pharma Cell culture process for making a glycoprotein
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
EA202090215A1 (ru) 2017-08-09 2020-07-01 Мерус Н.В. АНТИТЕЛА, СВЯЗЫВАЮЩИЕ EGFR И cMET
KR102119783B1 (ko) * 2017-08-14 2020-06-08 사회복지법인 삼성생명공익재단 인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편
CN109912715A (zh) * 2017-12-13 2019-06-21 凯惠科技发展(上海)有限公司 一种EGFRvIII抗体及其偶联物、制备方法和应用
AU2018392334A1 (en) 2017-12-22 2020-05-28 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
CN111655722A (zh) 2018-01-31 2020-09-11 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
SG11202006310PA (en) 2018-02-28 2020-07-29 Regeneron Pharma Systems and methods for identifying viral contaminants
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
EP4317959A3 (en) 2018-03-19 2024-03-27 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
WO2020046793A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
BR112020026348A2 (pt) 2018-08-30 2021-03-30 Regeneron Pharmaceuticals, Inc. Método para avaliar a estequiometria e distribuição de tamanho de complexos de proteínas, para selecionar um medicamento de proteína principal e para caracterizar complexos de proteínas, e, composição farmacêutica
KR20210114927A (ko) 2019-01-16 2021-09-24 리제너론 파마슈티칼스 인코포레이티드 이황화 결합을 특징 짓는 방법
CA3135004A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
US20220380474A1 (en) * 2019-07-02 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Monoclonal antibodies that bind egfrviii and their use
CN114667450B (zh) 2019-09-24 2025-05-02 里珍纳龙药品有限公司 用于色谱介质的使用和再生的系统及方法
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
JP7682174B2 (ja) 2019-11-25 2025-05-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 非水性エマルションを使用した持続放出製剤
CA3165060C (en) 2020-01-21 2023-06-20 Yiming Zhao Deglycosylation methods for electrophoresis of glycosylated proteins
KR20230058094A (ko) 2020-08-31 2023-05-02 리제너론 파아마슈티컬스, 인크. 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략
MX2023006077A (es) 2020-11-25 2023-06-06 Regeneron Pharma Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
CN116710124A (zh) 2020-12-17 2023-09-05 瑞泽恩制药公司 包封蛋白质的微凝胶的制造
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
WO2022177676A1 (en) * 2021-02-16 2022-08-25 City Of Hope Anti-domain iv egfr antibodies and uses thereof
BR112023017442A2 (pt) 2021-03-03 2023-09-26 Regeneron Pharma Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica
US20220309215A1 (en) 2021-03-26 2022-09-29 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
JP2024521871A (ja) 2021-06-01 2024-06-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド マイクロチップキャピラリー電気泳動アッセイ及び試薬
IL309048A (en) 2021-06-22 2024-02-01 Regeneron Pharma Anti-EGFRVIII drug antibody conjugates and uses thereof
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
IL311527A (en) 2021-09-20 2024-05-01 Regeneron Pharma Methods for controlling antibody heterogeneity
US20240400697A1 (en) * 2021-09-29 2024-12-05 National Research Council Of Canada Humanized anti-egfr viii antibodies and antigen-binding fragments thereof
MX2024004107A (es) 2021-10-07 2024-04-19 Regeneron Pharma Sistemas y metodos para modelar y controlar el ph.
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
TW202330104A (zh) 2021-10-26 2023-08-01 美商再生元醫藥公司 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
EP4493921A1 (en) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
JP2025519057A (ja) * 2022-05-18 2025-06-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３８及び４－１ｂｂに結合する多重特異性抗原結合分子、並びにその使用
CN120418653A (zh) 2022-12-16 2025-08-01 里珍纳龙药品有限公司 评估色谱柱完整性的方法和系统
US20240248097A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024158880A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
US20240255519A1 (en) 2023-02-01 2024-08-01 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
TW202446462A (zh) 2023-02-22 2024-12-01 美商再生元醫藥公司 系統適用性參數及管柱老化
US20240366471A1 (en) 2023-05-01 2024-11-07 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
WO2024258870A2 (en) 2023-06-12 2024-12-19 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
WO2025014896A1 (en) * 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en) 2023-09-18 2025-03-20 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
WO2025072597A2 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU639726B2 (en) 1989-09-08 1993-08-05 Duke University Structural alterations of the egf receptor gene in human gliomas
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
AUPP380498A0 (en) 1998-05-29 1998-06-25 Biomolecular Research Institute Limited Egf receptor agonists and antagonists
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
US20040248196A1 (en) 2001-08-03 2004-12-09 Adams Timothy Edward Methods of screening based on the egf receptor crystal structure
CN104059147A (zh) 2003-06-27 2014-09-24 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
US20110142822A1 (en) * 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007143168A2 (en) 2006-06-02 2007-12-13 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP2167963B1 (en) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
WO2009067242A2 (en) * 2007-11-20 2009-05-28 Imclone Llc Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof
US20090269343A1 (en) * 2008-04-11 2009-10-29 Duke University Dual Specific Immunotoxin for Brain Tumor Therapy
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
EP2374481B1 (en) 2008-07-21 2015-11-04 Polytherics Limited Novel reagents and method for conjugating biological molecules
CN104447995A (zh) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
ES2661074T3 (es) 2009-06-02 2018-03-27 Regeneron Pharmaceuticals, Inc. Células deficientes de fucosilación
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
AU2010283632B2 (en) 2009-08-10 2016-08-25 Ucl Business Plc Reversible covalent linkage of functional molecules
CN102933236B (zh) 2010-04-15 2014-10-08 斯皮罗根有限公司 吡咯并苯二氮卓类及其结合物
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
EA033468B1 (ru) * 2011-03-29 2019-10-31 Immunogen Inc Способы получения конъюгата "антитело-майтансиноид"
ES2898854T3 (es) 2011-05-27 2022-03-09 Ambrx Inc Composiciones que contienen, métodos que implican, y usos de derivados de dolastatina enlazados con aminoácidos no naturales
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EA028457B1 (ru) 2011-10-14 2017-11-30 Медимьюн Лимитед Пирролобензодиазепины
CN104011018B (zh) 2011-10-14 2016-12-14 麦迪穆有限责任公司 可用于制备吡咯并苯并二氮杂卓的合成方法和中间体
JP6399930B2 (ja) 2011-10-14 2018-10-03 シアトル ジェネティクス，インコーポレーテッド ピロロベンゾジアゼピンおよび標的コンジュゲート
JP6393617B2 (ja) 2011-10-14 2018-09-19 シアトル ジェネティクス，インコーポレーテッド ピロロベンゾジアゼピンおよび標的コンジュゲート
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
HK1202252A1 (en) * 2011-11-16 2015-09-25 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
JP2015500287A (ja) 2011-12-05 2015-01-05 アイジェニカ・バイオセラピューティクス・インコーポレイテッドＩｇｅｎｉｃａ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 抗体−薬物のコンジュゲート、ならびに関連する化合物、組成物および方法
MY183572A (en) 2013-03-15 2021-02-26 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
EP3030581B1 (en) 2013-08-07 2021-01-20 Affimed GmbH Antibody binding sites specific for egfrviii
EA035809B1 (ru) 2014-03-11 2020-08-14 Регенерон Фармасьютикалс, Инк. АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ

Also Published As

Publication number Publication date
CN106459199B (zh) 2021-01-01
EP3126388B1 (en) 2019-05-08
EA035809B1 (ru) 2020-08-14
PL3126388T3 (pl) 2019-10-31
PH12016501680B1 (en) 2016-10-24
MA39313A1 (fr) 2018-01-31
BR112016020752B1 (pt) 2023-11-14
US20150259423A1 (en) 2015-09-17
US20210147557A1 (en) 2021-05-20
CN106459199A (zh) 2017-02-22
US20180312594A1 (en) 2018-11-01
US10738124B2 (en) 2020-08-11
PT3126388T (pt) 2019-08-20
KR102399005B1 (ko) 2022-05-17
MA39313B1 (fr) 2018-12-31
LT3126388T (lt) 2019-08-26
CY1121870T1 (el) 2020-10-14
US9475875B2 (en) 2016-10-25
RS59077B1 (sr) 2019-09-30
CA2940685C (en) 2023-10-24
MY178160A (en) 2020-10-06
BR112016020752A2 (pt) 2018-01-23
CA2940685A1 (en) 2015-09-17
WO2015138460A1 (en) 2015-09-17
SI3126388T1 (sl) 2019-08-30
JP2017510559A (ja) 2017-04-13
AU2015229591A1 (en) 2016-09-29
KR20160131026A (ko) 2016-11-15
US11608380B2 (en) 2023-03-21
ME03525B (me) 2020-04-20
EA201691824A1 (ru) 2016-12-30
US10047160B2 (en) 2018-08-14
SMT201900439T1 (it) 2019-09-09
HUE045307T2 (hu) 2019-12-30
PH12016501680A1 (en) 2016-10-24
HRP20191335T1 (hr) 2019-10-18
IL247407A0 (en) 2016-11-30
ES2736126T3 (es) 2019-12-26
EP3126388A1 (en) 2017-02-08
MX373280B (es) 2020-04-16
US20160304615A1 (en) 2016-10-20
NZ724229A (en) 2023-06-30
DK3126388T3 (da) 2019-07-29
MX2016011619A (es) 2016-12-12
CL2016002252A1 (es) 2017-06-30
JP6632984B2 (ja) 2020-01-22
ZA201605894B (en) 2019-07-31
AU2015229591B2 (en) 2020-10-22
IL247407B (en) 2020-05-31

Similar Documents

Publication Publication Date Title
IL283321A (en) Antibodies against muc16 and their uses
IL285375B1 (en) IL-8-binding antibodies and their uses
IL258284A (en) Anti-Lag 3 antibodies and their uses
IL252804B (en) Anti-c10orf54 antibodies and their use
IL251248A0 (en) Anti-interleukin-33 antibodies and their uses
IL257263A (en) Antibodies against angptl8 and their use
ZA201605894B (en) Anti-egfrviii antibodies and uses thereof
IL251000A0 (en) Anti-glucagon antibodies and their uses
IL254955A0 (en) Anti-pacap antibodies and their uses
GB201403875D0 (en) Novel antibodies and uses thereof
GB201413913D0 (en) Novel antibodies and uses thereof
HUE050596T2 (hu) Antitestek CD73 ellen és azok felhasználásai
IL247315B (en) Anti-acth antibodies and their uses
ZA201701663B (en) Anti-il-25 antibodies and uses thereof
PT3292154T (pt) Anticorpos anti-her3 humano e seus usos
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof